Additionally, several clinical trials are currently investigating the therapeutic potential of targeting anti-MPO in various conditions, including sepsis, systemic lupus erythematosus, rheumatoid arthritis, small-vessel vasculitis, inflammatory bowel disease, cancer, and glomerulonephritis7,13,31,47,48. The gene discussed is MPO; the disease is systemic lupus erythematosus.